A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
155 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Buenos Aires, Argentina
- Novartis Investigative Site
Santa Fe, Argentina
- Novartis Investigative Site
Kogarah, New South Wales, Australia
- Novartis Investigative Site
Adelaide, South Australia, Australia
- Novartis Investigative Site
Clayton, Victoria, Australia
- Novartis Investigative Site
East Melbourne, Victoria, Australia
- Novartis Investigative Site
Melbourne, Victoria, Australia
- Novartis Investigative Site
Graz, Austria
- Novartis Investigative Site
Innsbruck, Austria
- Novartis Investigative Site
Linz, Austria
- Novartis Investigative Site
Rankweil, Austria
- Novartis Investigative Site
Salzburg, Austria
- Novartis Investigative Site
Steyr, Austria
- Novartis Investigative Site
Vienna, Austria
- Novartis Investigative Site
Brasschaat, Belgium
- Novartis Investigative Site
Bruges, Belgium
- Novartis Investigative Site
Leuven, Belgium
- Novartis Investigative Site
Lodelinsart, Belgium
- Novartis Investigative Site
Turnhout, Belgium
- Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
- Novartis Investigative Site
Curitiba, Paraná, Brazil
- Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
- Novartis Investigative Site
Florianópolis, Santa Catarina, Brazil
- Novartis Investigative Site
São Paulo, São Paulo, Brazil
- Novartis Investigative Site
São Paulo, São Paulo, Brazil
- Novartis Investigative Site
Rio de Janeiro, Brazil
- Novartis Investigative Site
Sao Paulo - SP, Brazil
- Novartis Investigative Site
Toronto, Ontario, Canada
- Novartis Investigative Site
Montreal, Quebec, Canada
- Novartis Investigative Site
Québec, Quebec, Canada
- Novartis Investigative Site
Sherbrooke, Quebec, Canada
- Novartis Investigative Site
Québec, Canada
- Novartis Investigative Site
Brno, Czechia
- Novartis Investigative Site
Ostrava, Czechia
- Novartis Investigative Site
Prague, Czechia
- Novartis Investigative Site
Prague, Czechia
- Novartis Investigative Site
Prague, Czechia
- Novartis Investigative Site
Aarhus, Denmark
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Jun 2014
- Primary completion
- 30 Apr 2016
- Completion
- 30 Apr 2016
- Last update posted
- 12 Dec 2017
- Registered enrollment
- 356
- Registry id
- NCT02158936
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.